Central European Journal of Medicine

, Volume 4, Issue 1, pp 32–36 | Cite as

Coronary artery atherosclerosis in patients with the initial and the early stage of chronic renal failure

  • Piotr Bartnicki
  • Robert Stolarek
  • Jacek Rysz
Research Article


The recent clinical data indicate that the initial and the early stages of chronic renal failure (CRF) may lead to increased incidence of cardiovascular complications and increased extent of coronary artery disease (CAD). This retrospective study was aimed to determine the effects of coexisting diabetes mellitus type 2 (DM-2) and the extent of atherosclerosis in coronary vessels in patients with mildly reduced kidney function (glomerular filtration rate GFR = 89–60 ml/min) and moderately reduced kidney function (GFR = 59–30 ml/min). The study patients included 53 subjects with creatinine concentration above 120 μmol/l as a cut-off level for the initial stage and compensated CRF. The distributions of coronary artery stenosis were also analysed with respect to DM-2 coexistence and levels of haemoglobin glikolised (HbA1c). The odds ratio of pathological changes in coronary arteries in patients with GFR = 44–30 ml/min, with respect to the number of affected vessels — only one, more than one or more than two — were 7.22, 4.90 and 3.55, respectively. In CRF patients with GFR = 60–89 ml/min the odds ratio of one, more than one and more than two vessels with stenosis and CAD was 1.93, 1.70 and 1.53, respectively. DM-2 was not related to the risk of significant coronary artery stenosis and did not enhance the pre-existing changes in the study setting. Our results demonstrate that the initial and the early stages of CRF were significant risk factors for coronary stenoses and for enhancing the pre-existing changes.


Chronic renal failure Coronary artery disease 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Foley R.N., Parfrey P.S., Sarnak M.J., Clinical epidemiology of cardiovascular disease in chronic renal disease, Am. J. Kidney Dis., 1998, 32, S112–S119PubMedCrossRefGoogle Scholar
  2. [2]
    Levin A, Foley R.N., Cardiovascular disease in chronic renal insufficiency, Am. J. Kidney Dis., 2000, 36, S24–S30PubMedCrossRefGoogle Scholar
  3. [3]
    Collins A.J., Cardiovascular mortality in end-stage renal disease, Am. J. Med. Sci., 2003, 325, 163–167PubMedCrossRefGoogle Scholar
  4. [4]
    Levey A.S., Eknoyam G., Cardiovascular disease in chronic renal disease, Nephrol. Dial. Transplant., 1999, 14, 828–833PubMedCrossRefGoogle Scholar
  5. [5]
    Harnett J.D., Foley R.N., Kent G.M., Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors, Kidney Int., 1995, 47, 884–890PubMedCrossRefGoogle Scholar
  6. [6]
    Sarnak M.J., Levey A.S., Schoolwerth A.C., Kidney disease as a risk factor for development of cardiovascular disease. A statement from the AHA councils on kidney in cardiovascular disease. High Blood Pressure Research, Clinical cardiology and epidemiology and prevention, Circulation, 1993, 108, 2154–2169CrossRefGoogle Scholar
  7. [7]
    Al-Ahmad A., Sarnak M.J., Salem D.N., Konstam M.A., Cause and management of heart failure in patients with chronic renal disease, Semin. Nephrol., 2001, 21, 3–12PubMedCrossRefGoogle Scholar
  8. [8]
    Horl W.H., Atherosclerosis and uremic retention solutes, Nephrology Forum, Kidney Int., 2004, 66, 1719–1731PubMedCrossRefGoogle Scholar
  9. [9]
    Sorensen C.R., Brendorp B., Rask-Madsen C., The prognostic importance of creatinine clearance after acute myocardial infarction, Eur. Heart J., 2002, 23, 948–952PubMedCrossRefGoogle Scholar
  10. [10]
    Tokmakova M.P., Skali H., Kenchaiah S., Chronic kidney disease, cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction: The Survival and Ventricular Enlargement (SAVE) study, Circulation, 2004, 110, 3667–3673PubMedCrossRefGoogle Scholar
  11. [11]
    Anavekar N.S., McMurray J.J.V., Velazquez E.J., Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction, N. Engl. J. Med., 2004, 351, 1285–1295PubMedCrossRefGoogle Scholar
  12. [12]
    Amann K., Tyralla K., Cardiovascular changes in chronic renal failure — pathogenesis and therapy, Clinical Nephrol., 2002, 58, S62–S72Google Scholar
  13. [13]
    Dries D.L., Exner D.V., Domanski M.J., The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction, J. Am. Coll. Cardiol., 2000, 35, 681–689PubMedCrossRefGoogle Scholar
  14. [14]
    Go A.S., Chertow G.M., Fan D., Chronic kidney disease and the risks of death, cardiovascular events and hospitalisation, N. Engl. J. Med., 2004, 351, 1296–1305PubMedCrossRefGoogle Scholar
  15. [15]
    Munter P., He J., Hamm L., Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States, J. Am. Soc. Nephrol., 2002, 13, 745–753Google Scholar
  16. [16]
    Rysz J., Banach M., Stolarek R.A., Pasnik J., Cialkowska-Rysz A., Koktysz R., et al., Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy, J. Nephrol., 2007., 20, 444–52PubMedGoogle Scholar
  17. [17]
    Selcoki Y., Turgut F., Kanbay M., Ozkara A., Tekin O., Uz B., et al., Cardiac valve calcifications and predictive parameters in hemodialysis patients, Cent. Eur. J. Med., 2007, 2, 304–31CrossRefGoogle Scholar
  18. [18]
    Rysz J., Błaszczak R., Banach M., Kedziora-Kornatowska K., Kornatowski T., Tański W., et al., Evaluation of selected parameters of the antioxidative system in patients with type 2 diabetes in different periods of metabolic compensation, Arch. Immunol. Ther. Exp., 2007, 55, 335–40CrossRefGoogle Scholar
  19. [19]
    Bachórzewska-Gajewska H., Małyszko J., Sitniewska E., Małyszko J., Dobrzycki S., Prevention of contrast-induced nephropathy in patients undergoing percutaneous coronary interventions in everyday clinical practice, Arch. Med. Sci., 2006, 2, 256–261Google Scholar
  20. [20]
    Rysz J., Kocur E., Blaszczak R., Bartnicki P., Stolarek R.A., Piechota M., IL-2, IL-6 and IL-8 levels remain unaltered in the course of immunosuppressive therapy after renal transplantation, Cent. Eur. J. Med., 2008, 3, 199–202CrossRefGoogle Scholar

Copyright information

© © Versita Warsaw and Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  1. 1.Department of Nephrology, Hypertension and Family MedicineMedical UniversityLodzPoland

Personalised recommendations